In a significant move within the pharmaceutical industry, the Catanese company Sifi is transitioning ownership to the Spanish pharmaceutical giant Faes Farma. Founded in 1935 and headquartered in Catania (Italy), it has established itself as a leader in the ophthalmic sector, boasting a comprehensive portfolio of products and a strong international presence.
The transaction, subject to certain conditions, involves the complete transfer of 100% of Sifi’s shares to Faes Farma, a publicly traded pharmaceutical company listed on the Madrid stock exchange. This strategic acquisition aims to strengthen Faes Farma’s position in ophthalmology, an area where the Catanese company has built a formidable reputation for quality, innovation, and long-term commitment. According to a joint statement, the agreement underscores the unique business model of Sifi, which combines well-established pharmaceutical and surgical units with rapidly growing divisions in contract manufacturing and rare diseases.
One of the key benefits of this acquisition is the complementary geographic footprint. Sifi’s presence in Italy, particularly its advanced manufacturing facilities in Aci Sant'Antonio, will enable Faes Farma to expand its product offerings in ophthalmology. Sifi’s two state-of-the-art plants produce ophthalmic medications and intraocular lenses, supported by long-term production contracts that ensure recurring revenue streams. These facilities will also help optimize Faes Farma’s manufacturing capabilities and operational efficiency. Furthermore, the integration with Laboratorios Edol, a prominent Portuguese pharmaceutical company recently acquired by Faes Farma, positions ophthalmology as a central strategic area for the group. The combined expertise and product portfolios are expected to generate significant synergies and foster innovation within the sector.
Fabrizio Chines, CEO of Sifi and a member of the founding family, expressed enthusiasm about the deal: “Faes Farma shares our values, culture, and vision. This acquisition will serve as a cornerstone for the group's ambitious expansion in ophthalmology, an area synonymous with quality and innovation. It also allows us to accelerate growth, unlock synergies, and create long-term value for stakeholders, especially by increasing global access to our medicines and devices.”
